ES2890818T3 - Una nueva subpoblación de Treg CD8+CD45RCbajas y usos de la misma - Google Patents

Una nueva subpoblación de Treg CD8+CD45RCbajas y usos de la misma Download PDF

Info

Publication number
ES2890818T3
ES2890818T3 ES16769882T ES16769882T ES2890818T3 ES 2890818 T3 ES2890818 T3 ES 2890818T3 ES 16769882 T ES16769882 T ES 16769882T ES 16769882 T ES16769882 T ES 16769882T ES 2890818 T3 ES2890818 T3 ES 2890818T3
Authority
ES
Spain
Prior art keywords
human
cells
treg
cd45rclow
treg cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16769882T
Other languages
English (en)
Spanish (es)
Inventor
Carole Guillonneau
Ignacio Anegon
Séverine Bezie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Nantes
Nantes Université
Original Assignee
Universite de Nantes
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Nantes, Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Universitaire de Nantes filed Critical Universite de Nantes
Application granted granted Critical
Publication of ES2890818T3 publication Critical patent/ES2890818T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES16769882T 2015-09-07 2016-09-06 Una nueva subpoblación de Treg CD8+CD45RCbajas y usos de la misma Active ES2890818T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306366 2015-09-07
PCT/EP2016/070991 WO2017042170A1 (en) 2015-09-07 2016-09-06 A new subpopulation of cd8+cd45rclow tregs and uses thereof

Publications (1)

Publication Number Publication Date
ES2890818T3 true ES2890818T3 (es) 2022-01-24

Family

ID=54196910

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16769882T Active ES2890818T3 (es) 2015-09-07 2016-09-06 Una nueva subpoblación de Treg CD8+CD45RCbajas y usos de la misma

Country Status (13)

Country Link
US (1) US20180251731A1 (cg-RX-API-DMAC7.html)
EP (1) EP3347452B1 (cg-RX-API-DMAC7.html)
JP (2) JP2018527932A (cg-RX-API-DMAC7.html)
KR (1) KR102768442B1 (cg-RX-API-DMAC7.html)
CN (1) CN108291203A (cg-RX-API-DMAC7.html)
AU (1) AU2016318762B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018004454A2 (cg-RX-API-DMAC7.html)
CA (1) CA2997646C (cg-RX-API-DMAC7.html)
ES (1) ES2890818T3 (cg-RX-API-DMAC7.html)
IL (1) IL257891B (cg-RX-API-DMAC7.html)
MX (1) MX390494B (cg-RX-API-DMAC7.html)
WO (1) WO2017042170A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201801265B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042179A1 (en) * 2016-10-31 2018-05-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene
EP4417210A1 (en) 2017-03-15 2024-08-21 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
EP3652306A1 (en) 2017-07-13 2020-05-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/-tregs
WO2019141774A1 (en) * 2018-01-19 2019-07-25 Miltenyi Biotec Gmbh Regulatory t cell expressing a chimeric antigen receptor
EP3749334B1 (en) 2018-02-08 2024-12-11 The Board of Trustees of the Leland Stanford Junior University Allogenic hematopoietic stem cell transplantation
CN111936180B (zh) * 2018-03-14 2024-04-05 热动力医疗公司 浮力激活细胞分选(bacs)兼容的激活/转导系统和方法
AU2019378883A1 (en) 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for T cell delivery
EP3894543A1 (en) * 2018-12-14 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8cd45rc low tregs
MX2021013227A (es) * 2019-04-30 2022-01-06 Univ California Expansion ex-vivo sin microesferas de celulas t reguladoras humanas.
AU2020327949A1 (en) * 2019-08-14 2022-03-03 The Regents Of The University Of California CAR-T cells specific for modified proteins in extracellular spaces
WO2024028486A1 (en) * 2022-08-04 2024-02-08 Nantes Universite In vitro method for obtaining clinical-grade cd8+ cd45rclow/- regulatory t cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001253400B2 (en) * 2000-04-11 2007-03-01 University Of Southern California A method to prevent graft rejection using tgf-beta to induce t suppressor cells
EP2126054B1 (en) * 2007-01-31 2016-07-06 Yeda Research And Development Company Limited Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
ES2702676T3 (es) * 2014-04-01 2019-03-04 Inst Nat Sante Rech Med Péptido de donante aislado derivado de MHC y usos del mismo
US10155025B2 (en) * 2014-07-17 2018-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for inhibiting or reducing transplant rejection by adminstration of interleukin-34

Also Published As

Publication number Publication date
AU2016318762A1 (en) 2018-03-22
RU2766691C2 (ru) 2022-03-15
JP7254128B2 (ja) 2023-04-07
CN108291203A (zh) 2018-07-17
BR112018004454A2 (pt) 2018-09-25
MX390494B (es) 2025-03-20
US20180251731A1 (en) 2018-09-06
IL257891A (en) 2018-05-31
KR102768442B1 (ko) 2025-02-17
RU2018107363A (ru) 2019-10-09
ZA201801265B (en) 2022-08-31
IL257891B (en) 2020-09-30
JP2018527932A (ja) 2018-09-27
WO2017042170A1 (en) 2017-03-16
EP3347452A1 (en) 2018-07-18
NZ740225A (en) 2025-05-30
CA2997646A1 (en) 2017-03-16
EP3347452B1 (en) 2021-06-23
MX2018002849A (es) 2018-09-05
JP2021183631A (ja) 2021-12-02
AU2016318762B2 (en) 2022-03-31
RU2018107363A3 (cg-RX-API-DMAC7.html) 2020-02-27
CA2997646C (en) 2024-04-23
KR20180054663A (ko) 2018-05-24

Similar Documents

Publication Publication Date Title
ES2890818T3 (es) Una nueva subpoblación de Treg CD8+CD45RCbajas y usos de la misma
Ferri et al. A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis
ES2765884T3 (es) Métodos de expansión y evaluación de linfocitos B y uso de linfocitos B expandidos para el tratamiento de enfermedades
Lerret et al. Donor-specific CD8+ Foxp3+ T cells protect skin allografts and facilitate induction of conventional CD4+ Foxp3+ regulatory T cells
ES2686593T3 (es) Expresión de CD127 que correlaciona inversamente con FoxP3 y la función supresora de Treg CD4+
JP6422344B2 (ja) 同種抗原反応性の制御性ｔ細胞を増大させる方法
JP6068432B2 (ja) 治療における調節性ｔ細胞の使用方法
US20120058096A1 (en) Compositions and methods for generating interleukin-35-induced regulatory t cells
JP2015513403A5 (cg-RX-API-DMAC7.html)
EP2558857B1 (en) New methods for isolating tr1 cells
KR20130093083A (ko) Il-13 생산 tr1-유사 세포 및 그의 용도
US20170216417A1 (en) Population of immunoregulatory t cells specific for an irrelevant antigen and uses thereof for preventing or treating immune diseases
FR2864546A1 (fr) Methode d'identification et de preparation de lymphocytes t regulateurs/suppresseurs, compositions et utilisations
CA3058284A1 (en) Methods to produce peptides, polypeptides or cells for modulating immunity
RU2766691C9 (ru) НОВАЯ СУБПОПУЛЯЦИЯ CD8+CD45RClow КЛЕТОК TREG И ЕЕ ПРИМЕНЕНИЯ
Ihantola T-cell dysfunction and autoantigen recognition in type 1 diabetes
Bischoff Chemokine-mediated modulation of autoimmunity in type 1 diabetes
Battaglia Induction of tolerance via T regulatory cells. A clinical reality or just a nice experiment in mice?